Prometrium Legal & Patent Challenges: What the FDA History Actually Means for You

When Was Prometrium FDA Approved, and Why Does That Date Matter?

The FDA approved Prometrium on May 14, 1998, making it the first oral micronized progesterone product to receive a full New Drug Application (NDA) approval in the United States. The manufacturer at the time was Solvay Pharmaceuticals; the brand was later acquired by AbbVie.

That 1998 date matters for a specific reason. Before Prometrium, the only FDA-approved oral progestogen widely used in hormone therapy was medroxyprogesterone acetate (MPA), a synthetic progestin. Micronized progesterone is chemically identical to the progesterone your ovaries produce. That structural difference drives meaningfully different effects on lipids, breast tissue, and sleep, a distinction the regulatory record has tried to capture, imperfectly, ever since.

What the Original Approval Covered

The original 1998 label approved Prometrium for two indications:

1. Prevention of endometrial hyperplasia in post-menopausal women with an intact uterus who are receiving conjugated estrogens.
2. Secondary amenorrhea.

Neither indication was fertility or luteal-phase support. Clinicians prescribing Prometrium for those purposes are doing so off-label, a fact the label makes plain and one worth knowing if you are using it during a fertility workup or an IVF cycle.

How the Approval Compared to European Regulation

The European Medicines Agency (EMA) had authorized similar micronized progesterone products (under the name Utrogestan and others) earlier in several EU member states. The EMA European Public Assessment Report (EPAR) framework provided post-market data that influenced U.S. Pharmacovigilance, particularly around venous thromboembolism (VTE) risk comparisons between micronized progesterone and synthetic progestins. An observational study published in the British Medical Journal found that oral micronized progesterone carried a lower VTE risk than synthetic progestins when combined with transdermal estradiol, a finding that fed back into how the FDA's Sentinel system monitored post-market signals for the U.S. Brand.

The Patent Field and Generic Competition

Patent expiry is not just a business story. For women, it determines whether you pay $30 or $300 per month for the same molecule.

The Original Patent Position

Solvay held composition-of-matter and formulation patents on the micronized particle size and the peanut oil suspension that gives Prometrium its bioavailability profile. Micronization matters clinically: unmicronized progesterone is poorly absorbed orally, so the particle-size technology was the core of the commercial advantage, not a trivial packaging detail.

Generic Entry and ANDA Challenges

Under the Hatch-Waxman Act, generic manufacturers file Abbreviated New Drug Applications (ANDAs) and can challenge innovator patents via Paragraph IV certifications, essentially arguing that the existing patent is invalid or will not be infringed by their product. Multiple generic manufacturers filed ANDAs for micronized progesterone capsules through the mid-2000s. By 2009, several ANDA-approved generics were available in the U.S. Market.

The practical result: brand Prometrium and its generics are considered therapeutically equivalent by the FDA (rated AB), meaning pharmacies can substitute generics without prescriber authorization in most states unless the prescriber writes "dispense as written."

What Therapeutic Equivalence Actually Means for You

AB-rated bioequivalence requires that the generic's area under the curve (AUC) and peak concentration (Cmax) fall within 80-125% of the brand's values in a crossover study. For most women, this range produces identical clinical effects. A small subset of women report symptom differences when switching between brand and a specific generic, likely driven by minor excipient differences or nocebo effects rather than true pharmacokinetic failure. If you notice a change in cycle regulation or side effects after a pharmacy switches your supply, ask your clinician to specify the manufacturer or write "dispense as written."

What the Prometrium Label Actually Says: A Section-by-Section Guide

The current prescribing information is the most underread document in women's health. Here is what each major section says, in plain language.

Indications: Narrow by Design

The FDA-approved indications remain the original two: endometrial protection during post-menopausal estrogen therapy, and secondary amenorrhea. The label does not cover:

• Luteal phase support in assisted reproduction
• Prevention of preterm birth (that indication belongs to hydroxyprogesterone caproate, Makena, a separate drug)
• Perimenopausal cycle irregularity
• Premenstrual syndrome or PMDD

This does not mean those uses are wrong; it means the evidence base for label expansion has not yet met the FDA's bar, or that sponsors have not pursued those indications commercially.

Contraindications: The Ones That Cannot Be Overlooked

The label lists the following absolute contraindications:

• Known hypersensitivity to progesterone or peanut oil (anaphylaxis has been reported)
• Undiagnosed abnormal vaginal bleeding
• Known or suspected breast cancer, or history of breast cancer
• Known or suspected estrogen- or progestogen-dependent neoplasia
• Active deep vein thrombosis, pulmonary embolism, or arterial thromboembolic disease
• Liver dysfunction or disease

The peanut oil contraindication deserves emphasis. Anaphylaxis to peanut-oil-containing progesterone capsules has been reported in women with confirmed peanut allergy. If you have any peanut sensitivity, this drug is not safe for you regardless of how mild your prior reactions have been. Compounded progesterone in an alternative base is the clinical workaround; your prescriber must know your allergy history.

Warnings and Precautions: Post-WHI Label Evolution

The Women's Health Initiative (WHI) trial published in 2002 implicated the MPA-plus-conjugated-equine-estrogen combination in elevated breast cancer and cardiovascular risk. Prometrium was not the progestogen studied in WHI, but the FDA required label updates across all progestogen-containing hormone therapy products. The current Prometrium label carries class-wide warnings about:

• Cardiovascular risk (stroke, VTE)
• Probable dementia (in women 65 and older in the WHI Memory Study)
• Breast cancer (class warning; the signal is weaker for micronized progesterone than for MPA based on observational data, but the label does not yet draw that distinction explicitly)

This is a critical gap between what the label says and what the evidence suggests. The landmark PEPI trial (JAMA 1995) showed that micronized progesterone preserved the HDL-cholesterol benefit of estrogen, while MPA abolished it, a finding that foreshadowed the mechanistic differences between these two progestogens. The WHI class-warning approach erases that distinction on the label, which is one reason informed prescribers and patients need to understand the underlying trial data, not just the label text.

Dosing Information on the Label

For post-menopausal endometrial protection: 200 mg orally once daily at bedtime for 12 days per 28-day cycle, combined with daily conjugated estrogens.

For secondary amenorrhea: 400 mg orally at bedtime for 10 days.

The label gives no dosing guidance for off-label uses. Fertility clinicians typically use 100-200 mg twice or three times daily for luteal phase support, based on institutional protocols and data from reproductive endocrinology literature rather than the FDA label.

Sex-Specific Pharmacology: How Your Hormonal Status Changes Everything

Micronized progesterone behaves differently depending on where you are in your reproductive life. This is not a minor nuance. It is the core clinical variable.

During Reproductive Years and Perimenopause

In cycling women, endogenous progesterone rises to 5-20 ng/mL in the luteal phase. Oral Prometrium 200 mg produces peak serum progesterone of roughly 17 ng/mL in post-menopausal women (per pharmacokinetic studies cited in the label), but absorption is highly variable. Eating a meal increases bioavailability by approximately 3-fold compared with fasting, making consistent administration with food (or at bedtime after an evening meal) clinically meaningful.

Perimenopausal women often have erratic progesterone production because ovulation becomes irregular. Using cyclical Prometrium (12-14 days per month) in this setting can regulate withdrawal bleeding and protect the endometrium, but the FDA indication does not cover perimenopause explicitly. Clinicians apply the post-menopausal endometrial protection data by extrapolation.

Post-Menopause

This is the population for which Prometrium is FDA-approved and most studied. The Menopause Society (formerly NAMS) 2022 hormone therapy position statement distinguishes micronized progesterone from synthetic progestins in its discussion of breast cancer risk, noting that observational data consistently show a lower breast cancer signal with micronized progesterone than with MPA, though randomized controlled trial data directly comparing the two in a breast-cancer endpoint trial do not exist.

During Fertility Treatment (Off-Label)

Prometrium is widely used in IVF cycles for luteal phase support. The American Society for Reproductive Medicine (ASRM) supports progesterone supplementation in IVF cycles, though the optimal route, dose, and duration remain under active study. Vaginal administration typically achieves higher endometrial tissue concentrations than oral dosing for the same serum level, which is why many reproductive endocrinologists prefer vaginal Prometrium or compounded progesterone in gel or suppository form for IVF, reserving oral dosing for cycles where serum levels rather than local uterine delivery are the primary target.

Pregnancy, Lactation, and Contraception: The Section You Cannot Skip

Pregnancy

Prometrium carries the legacy FDA Pregnancy Category B. This means animal reproduction studies have not demonstrated fetal risk, and there are no adequate, well-controlled studies in pregnant women. The category does not mean the drug is proven safe in pregnancy; it means the data to establish safety or harm is limited.

Progesterone is essential for maintaining early pregnancy, which is the biological rationale for its off-label use in threatened miscarriage and recurrent pregnancy loss. The PRISM trial (NEJM 2019) showed that vaginal micronized progesterone 400 mg daily (not oral Prometrium specifically) increased live birth rates in women with early pregnancy bleeding and a history of miscarriage, from approximately 72% in the placebo group to approximately 76% in the progesterone group in the overall cohort, with a larger effect in women with three or more prior miscarriages.

Prometrium capsules are not FDA-approved for use in pregnancy. Any use in a pregnant or potentially pregnant woman is off-label and requires explicit informed consent and specialist oversight. The peanut oil formulation also raises theoretical allergy concerns for the fetus in sensitized women, though clinical data on this specific risk are sparse.

Lactation

Progesterone is a normal component of breast milk and is present in higher concentrations in colostrum. Oral micronized progesterone does transfer into breast milk in small amounts. No studies have established the dose of progesterone an infant receives from a nursing mother taking Prometrium, nor are controlled safety studies available in lactating women. The label states that caution is warranted; the decision to use Prometrium while nursing should weigh the mother's clinical need against the theoretical infant exposure, and should involve a shared decision with the prescribing clinician.

Contraception

Prometrium is not a contraceptive. In perimenopausal women who are still ovulating, even cyclical progestogen does not reliably suppress ovulation. Women under 50 using Prometrium for perimenopausal symptom management should use a reliable contraceptive method if pregnancy is not desired. ACOG guidance on contraception in perimenopause notes that fertility does not drop to zero until 12 consecutive months of amenorrhea confirm menopause, meaning perimenopausal women remain at pregnancy risk for longer than many assume.

Who This Is Right For, and Who Should Use Caution

Understanding the regulatory history is only useful if it helps you figure out whether this drug is appropriate for your specific situation.

Women for Whom Prometrium Is a Strong Fit

• Post-menopausal women with an intact uterus taking systemic estrogen therapy, who want a progesterone that is bioidentical and has a more favorable lipid profile than MPA.
• Women with secondary amenorrhea who need a progestogen challenge to assess estrogen status.
• Perimenopausal women with heavy, irregular cycles whose clinician wants to protect the endometrium and who prefer a body-identical molecule over a synthetic progestin.

Women Who Need Extra Caution or a Different Option

• Women with confirmed peanut allergy: compounded micronized progesterone in an alternative base (sesame oil, olive oil) is the standard alternative.
• Women with a personal history of breast cancer: the label contraindication applies regardless of receptor status, though individual oncologist guidance may differ in specific clinical contexts.
• Women over 65 beginning hormone therapy for the first time: the WHI Memory Study signal for dementia risk applies as a class warning, and the benefit-risk calculation in this age group requires specialist input.
• Women who are pregnant or trying to conceive outside of a medically supervised protocol: oral Prometrium is not the appropriate formulation for most pregnancy-support indications, and self-prescribing without monitoring is not safe.

Prometrium Safety Signals: What Post-Market Surveillance Has Found

The FDA Sentinel system conducts ongoing safety monitoring of approved drugs using insurance claims and electronic health records from more than 100 million patients. Post-market surveillance of Prometrium and its generics has focused on three main signals.

Venous Thromboembolism

Observational data, most prominently from French cohort studies and the UK Biobank analyses, consistently show that transdermal estradiol combined with oral micronized progesterone carries a lower VTE risk than oral estradiol combined with synthetic progestins. One French cohort study of more than 80,000 women followed over four years found no increased VTE risk with transdermal estradiol plus micronized progesterone compared with non-users. The Prometrium label has not been updated to reflect this favorable signal, because the FDA requires randomized trial evidence for label claims, and no adequately powered VTE trial comparing micronized progesterone directly to MPA has been conducted.

Breast Cancer

The E3N cohort study from France, following 54,548 post-menopausal women, found that the combination of estradiol plus micronized progesterone was associated with no significant increase in breast cancer risk after a mean follow-up of 8.1 years, while estradiol combined with synthetic progestins was associated with a statistically significant increase. This finding does not appear in the Prometrium label; the class warning remains in place. The Menopause Society's 2022 position statement acknowledges this distinction and calls for a randomized trial to confirm it.

Sleep and Neurological Effects

Micronized progesterone is metabolized to allopregnanolone and other neuroactive steroids that act as positive allosteric modulators of GABA-A receptors. This produces the sedative effect many women notice at bedtime dosing, and may also contribute to the mood benefits some women report. No serious neurological safety signals have emerged from FDA Sentinel monitoring, but the sedative effect means Prometrium should not be taken before driving or operating machinery. The 200 mg dose produces more sedation than the 100 mg dose; the label recommends evening administration for this reason.

The Evidence Gap: Where Data in Women Is Thin

Women were underrepresented in clinical pharmacology trials through the 1980s. This matters directly for Prometrium because:

• The pharmacokinetic studies in the original NDA were conducted primarily in post-menopausal women on conjugated estrogens. Absorption data in cycling women, perimenopausal women not on estrogen, or women of varying BMI are limited.
• Body weight affects progesterone absorption. Higher fat mass may alter the distribution volume and effective serum level of oral micronized progesterone, but the label does not provide weight-based dosing guidance.
• Black and Hispanic women were underrepresented in the post-market observational studies most frequently cited for VTE and breast cancer comparisons. The safety signals described above may not apply uniformly across all racial and ethnic groups.

These are not reasons to avoid Prometrium. They are reasons to have a specific conversation with your clinician about whether standard dosing matches your individual physiology, and to report any unexpected symptoms to your prescriber promptly so that they enter the post-market surveillance record.

FAQ